Predictive Factors for Medullary Thyroid Cancer Aggressiveness (MYELO)

Predective Factors for Tumor Aggressiveness in Medullary Thyroid Cancer

This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.

Study Overview

• Status: Completed
• Conditions: Medullary Thyroid Cancer
• Intervention / Treatment: Procedure: Total Thyroidectomy

Detailed Description

This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival. The predictive factors included in this study are central and lateral compartment lymph node metastases as well as distant metastasis up to 1 year postoperatively, while biochemical predictors (meaning ratios such as lymphocyte to monocyte ratio etc and CEA and calcitonin drop levels) and histological predictors (such as nuclear atypia, amyloid, immunohistochemistry, desmoplasia) are included as secondary outcomes. In this study , patients >18 years old that underwent surgery for medullary thyroid cancer (total thyroidectomy, completion thyroidectomy) +/- central/lateral neck dissection) will be enrolled.

• Study Type: Observational
• Enrollment (Actual): 500

Contacts and Locations

Study Locations

• Austria
  • Salzburg, Austria
    • Department of Surgery, Saint John of God Hospital, Salzburg, Austria
• Belgium
  • Bruxelles, Belgium
    • Saint Luc, University Clouvain, Belgium
• Brazil
  • Santa Cruz Do Sul, Brazil
    • Head and Neck Surgery Department, Hospital Ana Nery, Santa Cruz do Sul, Brazil
• Bulgaria
  • Sofia, Bulgaria
    • University Clinic of Surgery, University Hospital "Lozenec"
• China
  • Hong Kong, China
    • Chinese University of Hong Kong
• Colombia
  • Manizales, Colombia
    • Head and Neck Department Oncologos del Occidente, Universidad de Caldas, Manizales, Colombia
• Croatia
  • Zagreb, Croatia
    • the University Hospital Center Sestre milosrdnice, Zagreb, Croatia, Department of Otorhinolaryngology and Head and Neck Surgery
• France
  • Brest, France
    • Head and Neck Surgery, Brest University Hospital, Brest, France
  • Poitiers, France
    • The University Hospital of Poitiers, France
• Greece
  • Athens, Greece
    • Thyroid Surgery Clinic IKE, Athens, Greece
  • Larissa, Greece
    • ENT Department University Hospital of Larissa
  • Patra, Greece
    • Department of Surgery, General University Hospital of Patras
  • Thessaloníki, Greece
    • Aristotle University of Thessaloniki
  • Thessaloníki, Greece
    • Gennimatas General Hospital
• India
  • Bhubaneswar, India
    • Department of ENT-Head and Neck Surgery, All India Institute of Medical Sciences, Bhubaneswar
  • Coimbatore, India
    • KMCH and KMCH Comprehensive Cancer Center
  • Madurai, India
    • Department of Endocrine and Breast Surgery at Sanjay Gandhi Post Graduate Institute of Medical Sciences
  • New Delhi, India
    • Department of Surgery, Maulana Azad Medical College & Lok Nayak Hospital
  • Vijayawada, India
    • Endocrine and Metabolic Surgery, Bhargav Endocrine Hospital, Vijayawada, India
• Iraq
  • Erbil, Iraq
    • University of Sulaimani | UNIVSUL ,Department of Surgery, Kurdistan
• Italy
  • Domodossola, Italy
    • ASL VCO - San Biagio Hospital - Domodossola (VB) - Italy
  • Genoa, Italy
    • Dipartimento di Scienze Chirurgiche (DISC), University of Genoa, Italy
  • Milan, Italy
    • Asst Santi Paolo e Carlo - Ospedale Polo Universitario San Paolo, Milan, Italy
  • Roma, Italy
    • UOC Chirurgia Endocrina e Metabolica, Fondazione Policlinico Universitario A Gemelli IRCCS
  • Trieste, Italy
    • Department of Medical and Surgical Sciences, University of Trieste, Cattinara Teaching Hospital, Trieste, Italy
  • Verona, Italy
    • Department of Surgery and Oncology, Endocrine Surgery Unit, Verona University Hospital
• Jordan
  • Zarqa, Jordan
    • Hashemite University of Zarqa
• Morocco
  • Marrakech, Morocco
    • Hepatobiliairy and endocrine surgery, Ibn Sina Hospital, Medical School of Medecine Rabat, Mohamed Vth University of Rabat Morocco
• Poland
  • Gdańsk, Poland
    • Division of General, Endocrine and Transplant Surgery, Medical University of Gdańsk
• Serbia
  • Belgrad, Serbia
    • Surgical Oncology Clinic, Institute for Oncology and Radiology of Serbia, Medical School, University of Belgrade
• Slovakia
  • Bratislava, Slovakia
    • Comenius University in Bratislava, Department of Paediatric Surgery, National Institute of Children's Diseases
  • Bratislava, Slovakia
    • Department of oncological surgery, St. Elisabeth cancer Institute
• Spain
  • Barcelona, Spain
    • Hospital Clinic (Barcelona, Spain)
  • Córdoba, Spain
    • Universitaria de Cordoba
  • Málaga, Spain
    • Hospital Regional de Malaga
  • Vigo, Spain
    • Department of General and Digestive Surgery, Division of Endocrine Surgery, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
• Switzerland
  • Bern, Switzerland
    • Bern University Hospital
  • Geneva, Switzerland
    • Geneva University Hospital
• Thailand
  • Bangkok, Thailand
    • Division of Endocrinology and Metabolism Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok, Thailand
• Turkey
  • Ankara, Turkey
    • Ankara University Faculty of Medicine, Department of Endocrine Surgery
  • Istanbul, Turkey
    • Acibadem MAA University
  • Istanbul, Turkey
    • Cerrahpasa medical faculty endocrine surgery department
  • Istanbul, Turkey
    • Department of Endocrin Pathology Unit, University of Health Sciences, Faculty of Medicine, Bakırköy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
• Ukraine
  • Kyiv, Ukraine
    • Endocrine surgeon-consultant, International medical center "CITIDOCTOR"
• United States
  • Oregon
    • Oregon City, Oregon, United States, 97239
      • Oregon Health & Science University, Oregon
• Vietnam
  • Việt Trì, Vietnam
    • Department of Radiology, Thien Hanh Hospital, Buon Ma Thuot, Vietnam

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients >18 years old who underwent surgery for medullary thyroid cancer are enrolled in this study

Description

Inclusion Criteria:

• Patients who underwent thyroidectomy for medullary thyroid cancer (total thyroidectomy, completion thyroidectomy) +/- central/lateral neck dissection

Exclusion Criteria:

• Age < 18 years

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Central lymph node metastasis	Central neck compartment lymph node metastasis	Number of lymph node Metastasis found in preoperative imaging studies or up to 1 year postoperatively
Lateral lymph node metastasis	Lateral neck compartment lymph node metastasis	Number of lymph node Metastasis found in preoperative imaging studies or up to 1 year postoperatively
Distant metastasis	Liver and lung metastasis	Number of distant Metastasis found in preoperative imaging studies or up to 1 year postoperatively

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nuclear atypia as histological predictor of aggressiveness	nuclear atypia	The pathology report is held immediately after surgery
Amyloid as histological predictor of aggressiveness	amyloid	The pathology report is held immediately after surgery
Immunohistochemistry as histological predictor of aggressiveness	immunohistochemistry	The pathology report is held immediately after surgery
Desmoplasia as histological predictor of aggressiveness	desmoplasia	The pathology report is held immediately after surgery
CEA as Biochemical predictor of aggressiveness	Carcinoembryonic antigen (CEA) preoperatively and up to 1 year postoperatively	pre and postoperative laboratory exams up to 1 year postoperatively
Calcitonin as Biochemical predictor of aggressiveness	calcitonin levels preoperatively and up to 1 year postoperatively	pre and postoperative laboratory exams up to 1 year postoperatively
White blood cell as Biochemical predictor of aggressiveness	white blood cell count	pre and postoperative laboratory exams up to 1 year postoperatively
Platelet count as Biochemical predictor of aggressiveness	platelet count	pre and postoperative laboratory exams up to 1 year postoperatively
CEA drop as Biochemical cure marker	CEA drop levels	up to 1 year postoperatively
Calcitonin drop as Biochemical cure marker	calcitonin drop levels	up to 1 year postoperatively

Collaborators and Investigators

• Sponsor: Aristotle University Of Thessaloniki
• Investigators: Principal Investigator: Theodossis Papavramidis, Prof, 1st Propedeutic Department of Surgery, AHEPA University Hospital of Thessaloniki, Greece

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2024
• Primary Completion (Actual): April 15, 2024
• Study Completion (Actual): April 15, 2024

Study Registration Dates

• First Submitted: February 19, 2024
• First Submitted That Met QC Criteria: March 1, 2024
• First Posted (Actual): March 5, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 2, 2025
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Aberrant Motor Behavior in Dementia; Endocrine System Diseases; Neoplasms by Site; Neoplasms; Behavioral Symptoms; Neoplasms by Histologic Type; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Thyroid Diseases; Carcinoma, Neuroendocrine; Aggression; Thyroid Neoplasms
• Other Study ID Numbers: MYELO

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No